Primary: Production and sales of cannabis in Canada. Later, broader markets, such as Europe. Emerald is science focused, is developing proprietary genetics, has PhD scientists and big-Pharma vets in senior management. Management is interested in the economic potential of CBD.

Secondary: Through the University of British Columbia, it is studying treatments of neurodegenerative and neuroinflammatory diseases, as well as metabolic and other diseases.

Risk of Prosecution for Marijuana-Related Companies. If you are considering investing in a company that is connected to the marijuana industry, be aware that marijuana-related companies may be at risk of federal, and perhaps state, criminal prosecution. The Department of Treasury recently issued guidance noting: “[T]he Controlled Substances Act (“CSA”) makes it illegal under federal law to manufacture, distribute, or dispense marijuana. Many states impose and enforce similar prohibitions. Notwithstanding the federal ban, as of the date of this guidance, 20 states and the District of Columbia have legalized certain marijuana-related activity.”